Author:
Hecht Anna,Meyer Julia A.,Behnert Astrid,Wong Eric,Chehab Farid,Olshen Adam,Hechmer Aaron,Aftandilian Catherine,Bhat Rukhmi,Choi Sung Won,Chonat Satheesh,Farrar Jason E.,Fluchel Mark,Frangoul Haydar,Han Jennifer H.,Kolb Edward A.,Kuo Dennis J.,MacMillan Margaret L.,Maese Luke,Maloney Kelly W.,Narendran Aru,Oshrine Benjamin,Schultz Kirk R.,Sulis Maria L.,Van Mater David,Tasian Sarah K.,Hofmann Wolf-Karsten,Loh Mignon L.,Stieglitz Elliot
Abstract
Mutations in the CBL gene were first identified in adults with various myeloid malignancies. Some patients with juvenile myelomonocytic leukemia (JMML) were also noted to harbor mutations in CBL, but were found to have generally less aggressive disease courses compared to patients with other forms of Ras pathway-mutant JMML. Importantly, and in contrast to most reports in adults, the majority of CBL mutations in JMML patients are germline with acquired uniparental disomy occurring in affected marrow cells. Here, we systematically studied a large cohort of 33 JMML patients with CBL mutations and found that this disease is highly diverse in presentation and overall outcome. Moreover, we discovered somatically acquired CBL mutations in 15% of pediatric patients who presented with more aggressive disease. Neither clinical features nor methylation profiling were able to distinguish patients with somatic CBL mutations from those with germline CBL mutations, highlighting the need for germline testing. Overall, we demonstrate that disease courses are quite heterogeneous even among patients with germline CBL mutations. Prospective clinical trials are warranted to find ideal treatment strategies for this diverse cohort of patients.
Publisher
Ferrata Storti Foundation (Haematologica)